SCHEMBL4144767

SCHEMBL4144767

Cc1n[nH]c2cc(Oc3cccc(F)c3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.48
FLT3 P36888 1/20 0.48
KDR P35968 7/20 0.45
CHEK1 O14757 5/20 0.45
FGFR1 P11362 2/20 0.45
LCK P06239 1/20 0.43
CDK4 P11802 1/20 0.43
CCND1 P24385 1/20 0.43
CCND3 P30281 1/20 0.43
ITK Q08881 1/20 0.41
MAP2K4 P45985 2/20 0.40
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
BTK Q06187 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
GCK P35557 2/20 0.39
NTRK1 P04629 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2448984 0.87 KDR (0.45) KDRCHEK1FGFR1LCKCDK4
SCHEMBL4144286 0.85 ALDH1A1 (0.49) KDRCHEK1FGFR1LCKCDK4
SCHEMBL16576449 0.85 KDR (0.59) KITFLT3KDRCHEK1FGFR1
SCHEMBL4134957 0.81 KDR (0.40) KDRCHEK1FGFR1LCKCDK4
SCHEMBL4144602 0.81 KDR (0.43) KITFLT3KDRCHEK1FGFR1
SCHEMBL27805303 0.80 KDR (0.47) KDRCHEK1FGFR1LCKCDK4
SCHEMBL4155522 0.79 NR1H2 (0.45) KDRCHEK1FGFR1GCK
SCHEMBL8212257 0.78 MAP2K4 (0.56) ITKMAP2K4
SCHEMBL27805305 0.75 CHEK1 (0.43) KDRCHEK1FGFR1PRMT5WDR77
SCHEMBL12907469 0.75 JAK2 (0.53) KDRCHEK1FGFR1CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143422-A1 P38 INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2009-06-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143422-A1 P38 INHIBITORS AND METHODS OF USE THEREOF MAPKAPK2, MAPK1, MAPK8 KIT 2859/4885FLT3 857/4885KDR 2788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.